Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2014 Oct;28(10):1960-8. doi: 10.1038/leu.2014.93. Epub 2014 Feb 28.

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

Author information

1
Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA.
2
Division of Hematology, University of Colorado, Denver, Aurora, CO, USA.
3
College of Pharmacy, The Ohio State University, Columbus, OH, USA.
4
Department of Chemistry, University of Rochester, Rochester, NY, USA.
5
Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Abstract

Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally defined leukemia stem cells, while sparing normal stem and progenitor cells. In addition to efficacy as single agents, flavaglines sensitize leukemia cells to several anticancer compounds, including front-line chemotherapeutic drugs used to treat leukemia patients. Mechanistic studies indicate that flavaglines strongly inhibit protein synthesis, leading to the reduction of short-lived antiapoptotic proteins. Notably though, treatment with flavaglines, alone or in combination with other drugs, yields a much stronger cytotoxic activity toward leukemia cells than the translational inhibitor temsirolimus. These results indicate that the underlying cell death mechanism of flavaglines is more complex than simply inhibiting general protein translation. Global gene expression profiling and cell biological assays identified Myc inhibition and the disruption of mitochondrial integrity to be features of flavaglines, which we propose contribute to their efficacy in targeting leukemia cells. Taken together, these findings indicate that rocaglamide and silvestrol are distinct from clinically available translational inhibitors and represent promising candidates for the treatment of leukemia.

PMID:
24577530
PMCID:
PMC4148474
DOI:
10.1038/leu.2014.93
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center